Skip to main content

Table 1 Other laboratory findings

From: Systemic inflammation and chronic kidney disease in a patient due to the RNASEH2B defect

Parameters Before tocilizumab 12 weeks after tocilizumab Before tofacitinib 48 weeks after tofacitinib Reference Range
Rheumatoid factor (IU/ml) 879 810 2615 2660 0–20
Protein in CSF (mg/L) 541.9 NA NA NA 150–450
WBCs in CSF (106/L) 1 NA NA NA 0–15
interferon-α in CSF (pg/ml) 22.1 NA NA NA NA
interferon-α in plasma (pg/ml) 1627 1040 2309 1601.4 139.64 ± 96.54
IP10 in plasma (pg/ml) 2172 2160 3702 2135 397.43 ± 159.51
IFNγ in plasma (pg/ml) 453.6 260.8 850.5 282.9 26.32 ± 11.24
TNFa in plasma (pg/ml) 335.4 232.9 554.6 259.1 42.05 ± 14.76
IL1β in plasma (pg/ml) 224.15 208 274.3 218 7.75 ± 6.5
IL4 in plasma (pg/ml) 311 135.6 473 252 29.81 ± 18.48
IL6 in plasma (pg/ml) 221 142.6 230.3 156.2 5.5 ± 3.39
IL10 in plasma (pg/ml) 1025 540.9 731.4 568.6 14.36 ± 9.88
IL12 in plasma (pg/ml) 1507 1389 1372 1337 149.32 ± 139.9
IL17A in plasma (pg/ml) 64.9 44.8 43.7 48 15.55 ± 10.13
GM-CSF in plasma (pg/ml) 1146 1053 1067 1073.6 68.36 ± 44.74